Nuclear morphometry and prognosis in favorable histology Wilms' tumor: A prospective reevaluation

Norman E. Breslow, Alan W. Partin, Benjamin R. Lee, Katherine A. Guthrie, J. Bruce Beckwith, Daniel M. Green

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: This study was designed to evaluate the ability of a previously published nuclear morphometry discriminant function to predict disease-free survival in patients with Wilms' tumor. Patients and Methods: We identified 218 patients with stage I-IV Wilms' tumor of favorable histology who were entered onto the National Wilms' Tumor Study (NWTS) between January 1, 1990 and April 15, 1994. The nuclear morphometry score was calculated for each patient as follows: MV(f) = (0.02 x AGE) + (1.17 x SNRF) + (90.6 x LEFD) - 94, with AGE denoting age at diagnosis in months, SNRF the skewness of the nuclear roundness factor, and LEFD the lowest value of nuclear ellipticity as measured by the feret diameter method. Relative risks of relapse were estimated for the total score and for each of its components. Sensitivity and specificity were determined for the criterion of 'MV(f) is greater than - 0.35' as a predictor of relapse. Results: By contrast with previously published results, neither the SNRF nor the LEFD made any contribution to the prediction of disease-free survival. Sensitivity and specificity of the criterion of 'MV(f) is greater than -0.35' were 71% and 56%, respectively. Conclusion: Re-evaluation of a published nuclear morphometry score showed that it did not predict disease-free survival in patients with Wilms' tumor. The earlier study very likely overestimated the predictive power of nuclear morphometry by using the same data set both to develop the score and to evaluate its properties. Because of the huge number of combinations of nuclear morphometry measurements that may enter into the multivariate discriminant function, use of appropriate statistical methods is essential to estimate accurately the sensitivity and specificity.

Original languageEnglish (US)
Pages (from-to)2123-2126
Number of pages4
JournalJournal of Clinical Oncology
Volume17
Issue number7
StatePublished - Jul 1999
Externally publishedYes

Fingerprint

Wilms Tumor
Histology
Disease-Free Survival
Sensitivity and Specificity
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Breslow, N. E., Partin, A. W., Lee, B. R., Guthrie, K. A., Bruce Beckwith, J., & Green, D. M. (1999). Nuclear morphometry and prognosis in favorable histology Wilms' tumor: A prospective reevaluation. Journal of Clinical Oncology, 17(7), 2123-2126.

Nuclear morphometry and prognosis in favorable histology Wilms' tumor : A prospective reevaluation. / Breslow, Norman E.; Partin, Alan W.; Lee, Benjamin R.; Guthrie, Katherine A.; Bruce Beckwith, J.; Green, Daniel M.

In: Journal of Clinical Oncology, Vol. 17, No. 7, 07.1999, p. 2123-2126.

Research output: Contribution to journalArticle

Breslow, NE, Partin, AW, Lee, BR, Guthrie, KA, Bruce Beckwith, J & Green, DM 1999, 'Nuclear morphometry and prognosis in favorable histology Wilms' tumor: A prospective reevaluation', Journal of Clinical Oncology, vol. 17, no. 7, pp. 2123-2126.
Breslow NE, Partin AW, Lee BR, Guthrie KA, Bruce Beckwith J, Green DM. Nuclear morphometry and prognosis in favorable histology Wilms' tumor: A prospective reevaluation. Journal of Clinical Oncology. 1999 Jul;17(7):2123-2126.
Breslow, Norman E. ; Partin, Alan W. ; Lee, Benjamin R. ; Guthrie, Katherine A. ; Bruce Beckwith, J. ; Green, Daniel M. / Nuclear morphometry and prognosis in favorable histology Wilms' tumor : A prospective reevaluation. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 7. pp. 2123-2126.
@article{b869dc5466f74d2fba9e8907292027a2,
title = "Nuclear morphometry and prognosis in favorable histology Wilms' tumor: A prospective reevaluation",
abstract = "Purpose: This study was designed to evaluate the ability of a previously published nuclear morphometry discriminant function to predict disease-free survival in patients with Wilms' tumor. Patients and Methods: We identified 218 patients with stage I-IV Wilms' tumor of favorable histology who were entered onto the National Wilms' Tumor Study (NWTS) between January 1, 1990 and April 15, 1994. The nuclear morphometry score was calculated for each patient as follows: MV(f) = (0.02 x AGE) + (1.17 x SNRF) + (90.6 x LEFD) - 94, with AGE denoting age at diagnosis in months, SNRF the skewness of the nuclear roundness factor, and LEFD the lowest value of nuclear ellipticity as measured by the feret diameter method. Relative risks of relapse were estimated for the total score and for each of its components. Sensitivity and specificity were determined for the criterion of 'MV(f) is greater than - 0.35' as a predictor of relapse. Results: By contrast with previously published results, neither the SNRF nor the LEFD made any contribution to the prediction of disease-free survival. Sensitivity and specificity of the criterion of 'MV(f) is greater than -0.35' were 71{\%} and 56{\%}, respectively. Conclusion: Re-evaluation of a published nuclear morphometry score showed that it did not predict disease-free survival in patients with Wilms' tumor. The earlier study very likely overestimated the predictive power of nuclear morphometry by using the same data set both to develop the score and to evaluate its properties. Because of the huge number of combinations of nuclear morphometry measurements that may enter into the multivariate discriminant function, use of appropriate statistical methods is essential to estimate accurately the sensitivity and specificity.",
author = "Breslow, {Norman E.} and Partin, {Alan W.} and Lee, {Benjamin R.} and Guthrie, {Katherine A.} and {Bruce Beckwith}, J. and Green, {Daniel M.}",
year = "1999",
month = "7",
language = "English (US)",
volume = "17",
pages = "2123--2126",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Nuclear morphometry and prognosis in favorable histology Wilms' tumor

T2 - A prospective reevaluation

AU - Breslow, Norman E.

AU - Partin, Alan W.

AU - Lee, Benjamin R.

AU - Guthrie, Katherine A.

AU - Bruce Beckwith, J.

AU - Green, Daniel M.

PY - 1999/7

Y1 - 1999/7

N2 - Purpose: This study was designed to evaluate the ability of a previously published nuclear morphometry discriminant function to predict disease-free survival in patients with Wilms' tumor. Patients and Methods: We identified 218 patients with stage I-IV Wilms' tumor of favorable histology who were entered onto the National Wilms' Tumor Study (NWTS) between January 1, 1990 and April 15, 1994. The nuclear morphometry score was calculated for each patient as follows: MV(f) = (0.02 x AGE) + (1.17 x SNRF) + (90.6 x LEFD) - 94, with AGE denoting age at diagnosis in months, SNRF the skewness of the nuclear roundness factor, and LEFD the lowest value of nuclear ellipticity as measured by the feret diameter method. Relative risks of relapse were estimated for the total score and for each of its components. Sensitivity and specificity were determined for the criterion of 'MV(f) is greater than - 0.35' as a predictor of relapse. Results: By contrast with previously published results, neither the SNRF nor the LEFD made any contribution to the prediction of disease-free survival. Sensitivity and specificity of the criterion of 'MV(f) is greater than -0.35' were 71% and 56%, respectively. Conclusion: Re-evaluation of a published nuclear morphometry score showed that it did not predict disease-free survival in patients with Wilms' tumor. The earlier study very likely overestimated the predictive power of nuclear morphometry by using the same data set both to develop the score and to evaluate its properties. Because of the huge number of combinations of nuclear morphometry measurements that may enter into the multivariate discriminant function, use of appropriate statistical methods is essential to estimate accurately the sensitivity and specificity.

AB - Purpose: This study was designed to evaluate the ability of a previously published nuclear morphometry discriminant function to predict disease-free survival in patients with Wilms' tumor. Patients and Methods: We identified 218 patients with stage I-IV Wilms' tumor of favorable histology who were entered onto the National Wilms' Tumor Study (NWTS) between January 1, 1990 and April 15, 1994. The nuclear morphometry score was calculated for each patient as follows: MV(f) = (0.02 x AGE) + (1.17 x SNRF) + (90.6 x LEFD) - 94, with AGE denoting age at diagnosis in months, SNRF the skewness of the nuclear roundness factor, and LEFD the lowest value of nuclear ellipticity as measured by the feret diameter method. Relative risks of relapse were estimated for the total score and for each of its components. Sensitivity and specificity were determined for the criterion of 'MV(f) is greater than - 0.35' as a predictor of relapse. Results: By contrast with previously published results, neither the SNRF nor the LEFD made any contribution to the prediction of disease-free survival. Sensitivity and specificity of the criterion of 'MV(f) is greater than -0.35' were 71% and 56%, respectively. Conclusion: Re-evaluation of a published nuclear morphometry score showed that it did not predict disease-free survival in patients with Wilms' tumor. The earlier study very likely overestimated the predictive power of nuclear morphometry by using the same data set both to develop the score and to evaluate its properties. Because of the huge number of combinations of nuclear morphometry measurements that may enter into the multivariate discriminant function, use of appropriate statistical methods is essential to estimate accurately the sensitivity and specificity.

UR - http://www.scopus.com/inward/record.url?scp=0033026226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033026226&partnerID=8YFLogxK

M3 - Article

C2 - 10561267

AN - SCOPUS:0033026226

VL - 17

SP - 2123

EP - 2126

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -